Johns Hopkins ABX Guide
Palivizumab
INDICATIONS
FDA
FDA
- Prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease (bronchopulmonary dysplasia, premature birth, and hemodynamically significant congenital heart disease).
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Treatment of severe RSV pneumonia in immunocompromised adult patients (limited data).
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: November 9, 2022
Citation
Pham, Paul A, and Paul G Auwaerter. "Palivizumab." Johns Hopkins ABX Guide, The Johns Hopkins University, 2022. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540413/all/Palivizumab.
Pham PA, Auwaerter PG. Palivizumab. Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540413/all/Palivizumab. Accessed November 21, 2024.
Pham, P. A., & Auwaerter, P. G. (2022). Palivizumab. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540413/all/Palivizumab
Pham PA, Auwaerter PG. Palivizumab [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. [cited 2024 November 21]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540413/all/Palivizumab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Palivizumab
ID - 540413
A1 - Pham,Paul,Pharm.D. BCPS
AU - Auwaerter,Paul,M.D.
Y1 - 2022/11/09/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540413/all/Palivizumab
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
